Introduction and Genomic Testing in Advanced Breast Cancer
Panelists discuss how integrating both tissue and liquid genomic testing at diagnosis and progression improves detection of tumor heterogeneity and informs personalized treatment decisions in metastatic breast cancer.
This section opens with moderator and panelist introductions, bringing together oncologists from top institutions. The discussion launches with Dr. Rao and the team discussing current best practices in genomic testing for metastatic breast cancer. Panelists highlight the importance of using both tissue and liquid (ctDNA) biopsies to capture tumor heterogeneity and inform personalized therapy. The consensus is to perform comprehensive genomic testing at both initial diagnosis and disease progression, leveraging the strengths of each method: tissue biopsies for mutation specificity and liquid biopsies for broader tumor evolution. Ultimately, the panel agrees that integrating both approaches is becoming the standard of care and sets the stage for deeper discussion of targeted treatments.
